Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.

Journal for immunotherapy of cancer - 1 Jul 2021

Çınar Özcan, Brzezicha Bernadette, Grunert Corinna, Kloetzel Peter Michael, Beier Christin, Peuker Caroline Anna, Keller Ulrich, Pezzutto Antonio, Busse Antonia

Abstract excerpt

BACKGROUND: Adoptive transfer of engineered T cells has shown remarkable success in B-cell malignancies. However, the most common strategy of targeting lineage-specific antigens can lead to undesirable side effects. Also, a substantial fraction of patients have refractory disease. Novel treatment approaches with more precise targeting may be an appealing alternative. Oncogenic somatic mutations represent ideal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell- and Tissue-Based Therapy
Share to Lymphoma, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 34330762
DOI: 10.1136/jitc-2021-002410
PMCID: PMC8327818

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.PMID 34330762Read ↗

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapySemantic proximity Read ↗

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.Semantic proximity Read ↗

Consequences of the recurrent MYD88L265P somatic mutation for B cell toleranceSemantic proximity Read ↗

Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.Semantic proximity Read ↗

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

[MyD88 L265P mutation and B cell tumor].Semantic proximity Read ↗

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.Semantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaSemantic proximity Read ↗

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.Semantic proximity Read ↗

Oncogenically active MYD88 mutations in human lymphoma.Semantic proximity Read ↗

Isolation of mitochondrial mutation-specific T cell receptors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.